New York Law Journal Recognizes Paul Hastings Life Sciences IP Litigators as New York Trailblazers

May 20, 2019

New York – The New York Law Journal has named

, , and to its inaugural list of New York Trailblazers, which honor innovators and thought leaders who have made significant marks on the practice, policy, and technological advancement of their practice.

The trio of Bruce Wexler, who chairs the firm’s Life Sciences practice, Eric Dittmann, global vice chair of the firm's Intellectual Property practice, and IP Litigation Partner Isaac Ashkenazi were noted for having litigated against virtually every generic drug manufacturer.

The New York Law Journal reported on a victory for Boehringer Ingelheim, where Wexler, Dittmann, and Ashkenazi led a team through fact, expert and Markman phases, obtaining six walk-away consent judgments from generics infringing patents relating to Boehringer’s blood thinning drug, Pradaxa.

Regarding the practice of life sciences patent litigation in the future, “The branded versus generic small molecule world will be around for a long time, and will be a part of our business,” said Isaac Ashkenazi. “The biosimilar world is really on its way up and it’s going to be a much larger part of life sciences practices.”

The Trailblazer profile can be read on page 26



The Paul Hastings Life Sciences practice has regularly been honored including:

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.

Practice Areas



Submission Requests
Corporate, Litigation, Real Estate, and Tax
Scott Wasserman
Intellectual Property, Life Sciences, and Employment
Becca Hatton
Katy Foster

Get In Touch With Us

Contact Us